Knowledge of the response of cytochrome P450 1B1 (CYP1B1) to exposure to 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) in both humans and rodents is limited. To improve the analysis of CYP1 proteins, specific CYP1B1 and CYP1A1 polypeptides were expressed as hexahistidinetagged fusion proteins in Escherichia coli, purified to homogeneity and used to produce polyclonal antibodies in rabbits. Immunoblot analyses showed that these antibodies were specific and sensitive, detecting both the human and rat forms of the respective isozymes and exhibiting negligible cross-reactivity between the two known CYP1 subfamilies. We show that CYP1B1, CYP1A1 and CYP1A2 protein levels were induced in the livers of female SpragueDawley rats following either acute (single dose of 25 µg TCDD/kg) or chronic (125 ng TCDD/kg/day for 30 weeks) exposure to TCDD. CYP1B1 protein exhibited a doseresponse to TCDD that was different from those of CYP1A1 and CYP1A2. CYP1B1 induction appeared to be less sensitive to TCDD exposure, with induction occurring at higher doses of TCDD than that required for induction of CYP1A1 or CYP1A2. Immunohistochemical analysis showed that in animals chronically exposed to TCDD (35 ng/kg/day for 30 weeks), CYP1B1 was induced only in centrilobular hepatocytes, a pattern of expression similar to that of CYP1A1 and CYP1A2. These observations of cellular co-localization of the CYP1 cytochromes in livers of TCDD-treated rats and apparent differences in both protein amounts and dose-response are indicative of both common and unique regulation of CYP1 induction.
Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD*, dioxin) and dioxin-like compounds are ubiquitous, persistent and lipophilic pollutants that bioaccumulate through the food chain, resulting in human exposure (1) . In rodent bioassays, TCDD induces tumor formation in multiple species, at multiple sites and in both sexes. Tumor incidence in the female Sprague-Dawley rat is widely used for the establishment of risk assessment guidelines for human exposure to TCDD and related com-pounds (2) . TCDD is a potent agonist of the aromatic hydrocarbon (Ah) receptor, and elicits a wide spectrum of biochemical and toxic responses in exposed animals (3) . While the mode of action of TCDD, via the Ah receptor, is conserved between rodents and humans, the sensitivity to specific toxic responses often varies widely. Further characterization of the biochemical effects of TCDD exposure should aid in our understanding of mechanisms that govern more complex biological responses, including cancer.
Previously, we reported the cloning of a TCDD-inducible cytochrome P450 (CYP) from both human and rat, defining a new cytochrome P450 subfamily, CYP1B1 (4) (5) (6) . The CYP1B1 protein has also been independently purified and its cDNA isolated from rat (7) and mouse (8, 9) . The cytochromes P450 play a key role in xenobiotic detoxification and in the metabolism of many endogenous substrates such as steroid hormones, fatty acids and prostaglandins (10) . Several of these enzymes are important in carcinogenesis and mutagenesis, since they are responsible for oxidative metabolism and activation of numerous procarcinogens. CYP1B1 catalyses estradiol hydroxylation (11, 12) and the activation of numerous polycyclic aromatic hydrocarbons and aryl amines (7, 13, 14) . Recently, truncating mutations in the CYP1B1 gene were identified as the principal cause of primary congenital glaucoma, a pathology associated with abnormal eye development (15) . This finding supports the hypothesis that CYP1B1 is involved in the metabolism of endogenous substrates that are involved in normal cell growth and differentiation. This current understanding of CYP1B1 suggests that this enzyme may be involved in multiple mechanisms of carcinogenesis, toxicity and disease; through the formation of potentially genotoxic metabolites of estrogens (6, 11) , the activation of procarcinogens (7, 13) and the alteration of cellular signaling pathways (15) .
One of the most understood responses of animals exposed to TCDD is the enhanced expression of CYP1A1 and CYP1A2. In contrast, knowledge of the response of CYP1B1 is limited. CYP1B1 RNA is detectable in a variety of human tissues (5, 13) and inducible by TCDD treatment in vitro (4, 5, 12) . In rats, CYP1B1 is normally expressed in the adrenal gland, testis and ovary (14) , and is induced in the liver, lungs and kidney of rats treated with either TCDD (6) or other Ah receptor agonists (7) . In order to improve our analyses of the CYP1 family proteins, selected CYP1B1 and CYP1A1 polypeptides were expressed as fusion proteins in Escherichia coli, purified and used to produce polyclonal antibodies. We demonstrated the specificity and sensitivity of these antibodies, and used these antibodies for the comparative immunological analysis of CYP1B1 and CYP1A1/CYP1A2 expression in the livers of female Sprague-Dawley rats. We show that CYP1B1 protein expression is induced following acute exposure to TCDD and that the dose-response for this induction differs from that of CYP1A1 and CYP1A2. We also show that CYP1B1 is induced following chronic exposure to TCDD at a non-toxic yet carcinogenic dose, and that CYP1B1 exhibits a centrilobularspecific pattern of induction by TCDD, similar to that of CYP1A1/1A2.
Materials and methods

Animal handling
For short-term acute treatment, female Sprague-Dawley rats were treated with a single dose of 25 µg TCDD (in corn oil)/kg body wt and killed 3 days later. The dose-response analyses used archived samples from a previous acute treatment study for which liver TCDD burdens were available (16) . In this study female Sprague-Dawley rats were treated with 0, 1, 10, 100, 1000 or 10 000 ng TCDD/kg body wt, and killed 4 days later. For chronic TCDD exposure we used archived liver samples obtained from female SpragueDawley rats treated bi-weekly with either 0.5 or 1.75 µg TCDD (in corn oil)/ kg body wt for 30 weeks (to approximate daily doses of 35.7 and 125 ng TCDD/kg body wt) (17, 18) . Control animals received corn oil alone.
Expression and purification of hexahistidine-tagged proteins in E.coli
For the generation of fusion proteins, cDNA constructs were cloned into a vector engineered such that the expressed protein has an amino terminal hexahistidine (His 6 ) peptide tag, thereby allowing affinity purification by metal chelate affinity chromatography.
For the human CYP1B1 expression construct (herein referred to as His 6 -CYP1B1), a 565 bp Xho I fragment of the human CYP1B1 cDNA (nucleotide positions, 842-1407; amino acid residues 166-349) (5) was subcloned into the Xho I site of pTrcHis A (Invitrogen, San Diego, CA, USA), and transformed into E.coli JM109 cells. For the human CYP1A1 expression construct (herein referred to as His 6 -CYP1A1), a 795 bp Pst I-Rsa I fragment of the human CYP1A1 cDNA (nucleotides 306-1101, amino acid residues 75-338) was subcloned into the Pst I-EcoR I site of pTrcHis C, following blunt-end fill-in of the EcoR I site using T4 DNA Polymerase, and transformed into E.coli Top 10 cells.
A freshly picked colony transformed with each respective expression construct was inoculated into 5 ml Terrific broth [1.2% (w/v) bacto-tryptone, 2.4% (w/v) bacto-yeast extract, 0.4% (v/v) glycerol, 17 mM KH 2 PO 4 , 72 mM K 2 HPO 4 ] containing 100 µg/ml ampicillin (TB ϩ Amp), and grown overnight at 37°C, 200 rpm. Overnight culture (500 µl) was inoculated into 25 ml (for His 6 -CYP1B1) or 50 ml (for His 6 -CYP1A1) TB ϩ Amp and grown at 37°C, 200 rpm until the cells were in mid-log phase (A 600 ϭ 0.7-0.9). Protein expression was induced by the addition of IPTG to a final concentration of 1 mM. Following overnight induction, 0.5 ml cells was pelleted by centrifugation, resuspended and boiled for 5 min in 100 µl SDS sample dilution buffer (50 mM Tris.Cl, pH 6.8, 1.5% 2-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% glycerol). A 15 µl lysate sample was analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to confirm induction of the 28 kDa His 6 -CYP1B1 or the 36 kDa His 6 -CYP1A1 proteins.
The induced E.coli culture was pelleted by centrifugation at 4000 g for 20 min at 4°C. Cells were resuspended and lysed in 6 M guanidinium hydrochloride, 100 mM sodium phosphate, 10 mM Tris.Cl, pH 8.0 and the hexahistidine-tagged proteins were purified by affinity column chromatography with nickel-nitrilotriacetic acid (NTA)-agarose (Qiagen, Chatsworth, CA, USA). Elution of His 6 -CYP1B1 from the NTA-agarose was achieved using a pH step-gradient (pH 8.3, pH 6.5, pH 4.0). Elution of His 6 -CYP1A1 was achieved using an imidazole step-gradient (0.01-0.25 M). Approximately 500 µg of affinity purified protein was then separated by SDS-PAGE using a 20-cm long 12% polyacrylamide gel and stained with 0.3 M copper chloride for 5 min followed by destaining in water (19) . The region of the gel containing the fusion protein was excised using a razor blade and destained by repeated washing in 0.25 M ethylenediaminetetra-acetic acid (EDTA), 0.25 M Tris.Cl, pH 9.0. Protein was eluted from the gel slice by electroelution in 25 mM Tris, 192 mM glycine, 0.01% SDS, then dialysed against ϫ0.5 phosphate buffered saline and frozen at -20°C. The purity of the electroeluted protein was confirmed by silver staining of the protein fractionated by SDS-PAGE.
Generation of polyclonal antibodies
All animal procedures were carried out by Spring Valley Laboratories (Sykesville, MD, USA). A polyacrylamide gel slice containing 250 µg purified fusion protein was minced and emulsified in complete Freund's adjuvant and used for primary subcutaneous immunizations of New Zealand White male rabbits. Rabbits were boosted 2 and 4 weeks following the primary immunization with 200 µg purified protein, emulsified in incomplete Freund's adjuvant. Serum used for immunological analyses was prepared from blood drawn 5 weeks following the primary immunization.
Immunoblot analysis
Microsomes from the AHH-1 TK Ϯ B-lymphoblastoid cell lines engineered to express either human CYP1A1 (cell line h1A1v2) or human CYP1A2 (cell line h1a2v2) were purchased from GENTEST Corporation (Woburn, MA, USA). Purified rat CYP1A1 and rat CYP1A2 proteins were a generous gift from Dr Joyce Goldstein at the National Institute of Environmental Health Sciences (Research Triangle Park, NC, USA). Microsomes from yeast expressing human CYP1B1 (herein referred to as CYP1B1∆3) were prepared as previously described (11) . Microsomal samples were solubilized in SDS sample dilution buffer and separated by denaturing SDS-PAGE. Separated proteins were electrophoretically transferred to nitrocellulose (Hybond ECL; Amersham Corporation, Arlington Heights, IL, USA) or polyvinylidene fluoride (PVDF) membranes (Immobilon-P; Millipore, Bedford, MA, USA). Incubation with primary antibody (rabbit anti-P450 serum diluted 1:2000) was for 1 h at room temperature. Bound antibody was detected by incubation for 1 h with a horseradish peroxidase (HRP) linked secondary antibody (goat anti-rabbit IgG, 1:30 000 dilution (Promega Corporation, Madison, WI, USA) or donkey anti-rabbit IgG, 1:10 000 dilution (Amersham Corporation, Arlington Heights, IL, USA)). Bound secondary antibody was detected by an enhanced chemiluminescence (ECL) method according to the manufacturer's instructions (Amersham Corporation).
Immunohistochemical analysis
Serial sections of archived formalin-fixed, paraffin-embedded liver samples (18) were cut at 4 µm. Serum IgG was purified by Protein A affinity purification (Pierce) and used at a concentration of either 8 µg/ml (CYP1A1) or 2.5 µg/ml (CYP1B1). Non-specific staining was assessed using normal rabbit serum (Sigma) at a dilution of 1:50 000. Specificity of staining was assessed by incubation of each antibody with a 6-fold molar excess of its respective purified fusion protein, prior to immunohistochemical analysis. Anti His 6 -CYP1A1 IgG (8 µg/ml) was incubated with the purified His 6 -CYP1A1 protein (12 µg/ml) and anti His 6 -CYP1B1 IgG (2.5 µg/ml) was incubated with purified His 6 -CYP1B1 protein (3 µg/ml). Each antibody was also incubated with a non-specific protein (human milk fat globulin) at the same concentration. Incubation of the antibodies with their respective fusion proteins eliminated staining, whereas incubation with the non-specific protein did not significantly affect specific immunoreactivity.
For the immunohistochemical procedure, the slides were deparaffinized in xylene (twice for 4 min) followed by washing in 100% ethanol (4 min), 95% ethanol (2 min), 80% ethanol (15 s) and distilled water. Immunostaining was performed on a Techmate 1000 automated stainer (Ventana-BioTek Solutions Inc., Santa Barbara, CA, USA) at room temperature. All solutions were supplied by the manufacturer. For antigen retrieval, the slides were transferred into a slide holder containing sodium citrate buffer and heated in a steamer for 20 min (Black and Decker Handy Steamer Plus). After blocking of the endogenous peroxidase activity with 3% H 2 O 2 for 15 min, the slides were washed with phosphate buffer for 1 min and incubated with primary antibody overnight. The incubations, both with the secondary antibody and the tertiary antibody complex (Avidin-Biotin complex), were performed for 30 min, interrupted by a 1-min washing with phosphate buffer. After development of the diaminobenzidine chromagen for 20 min, the slides were washed with distilled water for 1 min and counterstained for 1 min with hematoxilin.
Results
Expression of CYP1B1 and CYP1A1 in E.coli In order to obtain polyclonal antibodies to CYP1B1 and CYP1A1 that would be predicted to cross-react between rat and human isozymes, we designed expression constructs spanning a region that exhibited high sequence identity with the corresponding rat isozymes, yet had low sequence identity between the CYP1A and CYP1B1 subfamilies ( Figure 1B) . The sequence identity shared between CYP1A1 and CYP1A2 ( Figure 1D ) indicated that the antibodies raised to this region may cross-react with CYP1A2. We expressed these regions of CYP1B1 and CYP1A1 as hexahistidine-tagged fusion proteins in E.coli. High expression of His 6 -CYP1B1 and His 6 -CYP1A1 was observed when compared to extracts obtained from induced E.coli cultures transformed with the parent vector alone ( Figure  2A and 2B). Metal chelate affinity purification yielded fusion proteins with Ͼ70% purity as judged by SDS-PAGE ( Figure  2A and 2B, lane 3) . The CYP1B1 and CYP1A1 fusion proteins were predicted to be 28 kDa and 36 kDa, respectively, and this was confirmed by SDS-PAGE. Further purification by preparative SDS-PAGE yielded a single band for each expressed fusion protein (Figure 2A and 2B, lane 4) . The purity of the proteins was confirmed by silver staining (data not shown).
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Specificity and sensitivity of polyclonal antibodies to CYP1B1 and CYP1A1
Immunoblot analysis with the anti His 6 -CYP1B1 antibody showed that it specifically identified human CYP1B1 expressed in yeast microsomes (CYP1B1∆3), but did not exhibit any immunoreactivity with CYP1A1 or CYP1A2 expressed in the AHH-1 TK Ϯ B-lymphoblastoid cell line ( Figure 3A) . Immunoblot analysis using the anti His 6 -CYP1A1 antibody specifically reacted with CYP1A1 but not with microsomes containing expressed CYP1B1 ( Figure 3B ). As predicted from sequence comparisons of the CYP1A family ( Figure 1 ) the anti His 6 -CYP1A1 antibody also identified human CYP1A2 ( Figure 3B ). No immunoreactivity was observed with microsomes from either yeast containing the pYES2 expression vector alone or the parent AHH-1 TK Ϯ B-lymphoblastoid cell line, using either antibody, indicating that the immunoreactive bands identified by the antibodies corresponded to specific cytochrome P450 isozyme expression.
The sensitivity of each antibody was assessed by immunoblot analysis of serial dilutions of microsomal protein obtained from cells expressing the target P450 proteins. Cytochrome P450 content of the microsomal protein used as standards was determined spectrally. The data obtained indicate that the anti His 6 -CYP1B1 serum gave strong immunoreactivity with as little as 0.08 pmol CYP1B1 and could detect down to 0.01 pmol CYP1B1∆3 ( Figure 4A) . Sensitivity of the anti His 6 -CYP1A1 antibody was somewhat lower than that of the anti His 6 - CYP1B1 antibody, being able to detect as low as 0.2 pmol CYP1A1 ( Figure 4B ).
Immunoblot analysis of CYP1B1 and CYP1A1 in rat tissues
Immunoblot analysis using the anti His 6 -CYP1B1 serum specifically identified a 57 kDa band in rat adrenal glands ( Figure 5A , lane 7) and demonstrated no cross-reactivity with purified CYP1A1 or CYP1A2 ( Figure 5A , lanes 5 and 6). CYP1B1 is normally expressed as a 57 kDa protein in rat adrenal, indicating that the anti His 6 -CYP1B1 antibody specifically identified CYP1B1 in both rats and humans. Immunoblot analysis showed that CYP1B1 is undetectable in control female rat liver ( Figure 5A, lanes 1 and 3) . Treatment of female Sprague-Dawley rats with either a single high dose of 25 µg TCDD/kg (and killed 3 days later) or a carcinogenic dose of 125 ng TCDD/kg/day for 30 weeks resulted in a significant increase in the expression of the 57 kDa CYP1B1 protein in rat liver ( Figure 5A, lanes 2 and 4) . By comparison the expression of CYP1B1 in TCDD-treated rat liver was Ͼ10-fold lower than the level of expression observed in unexposed rat adrenal.
Immunoblot analysis using the anti His 6 -CYP1A1 antibody showed that it specifically recognized purified CYP1A1 and CYP1A2 ( Figure 5B , lanes 5 and 6) and identified two bands in microsomes obtained from TCDD-treated animals ( Figure  5B, lanes 2 and 4) . This was consistent with the expected induction of both CYP1A1 (55 kDa) and CYP1A2 (52 kDa) in rat liver following TCDD exposure. Consequently, as predicted by sequence analysis of the CYP1A1 fusion protein (Figure 1) , the anti His 6 -CYP1A1 antibody specifically reacted with both purified rat CYP1A1 and rat CYP1A2. An immunoreactive band was also observed in rat adrenals and this comigrated with rat CYP1A2 ( Figure 5B, lane 7) .
Comparative dose-response relationships for the CYP1 cytochromes P450
Immunoblot analysis indicated that the expression of CYP1B1 following acute exposure (3 days following a single dose of 25 µg TCDD/kg) was higher than that following chronic exposure (125 ng TCDD/kg/day for 30 weeks) ( Figure 5A ). CYP1A1 and CYP1A2 are near maximally induced following chronic exposure to 125 ng/kg/day (17) . The higher induction of CYP1B1 in acute treated animals suggested that CYP1B1 expression was not maximal following chronic treatment and that CYP1B1 may be less responsive to TCDD than CYP1A1 or CYP1A2. To address this question, we analysed the expression of CYP1B1, CYP1A1 and CYP1A2 in the livers of female Sprague-Dawley rats 4 days after a single dose of either 0, 1, 10, 100, 1000 or 10 000 ng TCDD/kg body wt ( Figure 6 ). CYP1B1 expression in rats given a single dose of 10 000 ng/kg was induced relative to the expression in control animals ( Figure 6A ). By comparison, CYP1A1 and CYP1A2 were induced at 100 ng/kg ( Figure 6B ). A single dose of 100, 1000 and 10 000 ng TCDD/kg results in liver TCDD levels of 0.4, 6.9 and Ͼ124 ppb, respectively (16) . These data indicate that the CYP1A and CYP1B1 isozymes exhibit a different dose-response to TCDD, and that CYP1B1 may be less sensitive to induction by TCDD.
Immunohistochemical analysis of CYP1B1 and CYP1A1 in rat liver
The observation that CYP1B1, CYP1A1 and CYP1A2 exhibited differential dose-responses prompted us to analyse whether the induction of these isozymes occurred in the same areas of the liver. To address this, we conducted an immunohistochemical analysis of CYP1B1 and CYP1A expression in the livers of female rats treated with 35 ng TCDD/kg/ day for 30 weeks ( Figure 7) . In a previous study, Tritscher and co-workers demonstrated expression of CYP1A1 and CYP1A2 in centrilobular regions of TCDD treated rat liver (17) . We therefore made new slides from tissue blocks used in this previous study for comparison of CYP1B1 and CYP1A expression.
Analysis of the livers of untreated rats showed no staining for CYP1B1 ( Figure 7C ). By comparison, analysis of untreated 399 animals with the anti His 6 -CYP1A1 antibody showed staining in centrilobular hepatocytes in acinar zone 3 ( Figure 7E ). This observation is consistent with the previous studies showing expression of CYP1A2 in centrilobular hepatocytes (17) . It is noteworthy that centrilobular-specific patterns of expression have also been observed for phenobarbital-inducible cytochromes P450 (20) .
Following treatment of female Sprague-Dawley rats with 35 ng TCDD/kg/day for 30 weeks, there was marked cytoplasmic staining of centrilobular hepatocytes in acinar zone 3 using the anti His 6 -CYP1B1 antibody ( Figure 7D ). Negligible staining was observed in periportal hepatocytes (acinar zone 1), indicating that CYP1B1 exhibits an acinar-dependent pattern of induction by TCDD. Nuclear staining in the hepatocytes was also observed in both control and TCDD-treated livers using the anti His 6 -CYP1B1 antibody. However, no expression of the 57 kDa CYP1B1 protein was observed following immunoblot analysis of rat liver nuclear extracts using the anti His 6 -CYP1B1 antibody (data not shown) suggesting that the observed nuclear staining was not due to CYP1B1 expression.
The anti His 6 -CYP1A1 antibody also exhibited marked staining of centrilobular hepatocytes (acinar zone 3), but much less staining of periportal hepatocytes (acinar zone 1) of TCDD-treated animals ( Figure 7F ). Compared with untreated animals, there was a clear increase in the intensity of staining, and number of cells staining positive for the CYP1A isozymes. This is similar to previous studies (17, 21) and is consistent with the hypothesis that the shape of the dose-response curve for CYP1A induction in the whole liver is a function of both an increase in response within an individual cell and also an increase in the number of cells maximally responding.
No staining in the liver was obtained using normal rabbit serum as the primary antibody instead of either the anti His 6 -CYP1A1 or anti His 6 -CYP1B1 antibodies ( Figure 7A,B) , or following incubation of the respective antibodies with their respective purified fusion proteins (data not shown). Immunohistochemistry was also performed with and without antigen retrieval . There was no significant difference in overall protein detection between the two methods although protein detection seemed to be slightly stronger after antigen retrieval. However, it was noted that nuclear staining was observed using the antiHis 6 -CYP1B1 antibody after antigen retrieval, which was not observed when using the antibody without antigen retrieval.
Discussion
CYP1B1 is a recently identified cytochrome P450 that is inducible by TCDD in both rodents and humans. To aid studies understanding the function and regulation of expression of CYP1B1, as well as its role in the development of pathologies associated with TCDD exposure, we wanted to develop antibodies that would be specific for both rat and human CYP1B1. Since our approach to the isolation and analysis of CYP1B1 has been a molecular genetic one, we chose to produce the antigen using a recombinant DNA method. In this paper we report the production and characterization of antibodies raised against hexahistidine-tagged fusion proteins of CYP1B1 and CYP1A1 that were produced and purified from bacteria. We used these antibodies to demonstrate that CYP1B1 is inducible by TCDD, exhibits a centrilobular-specific pattern of expression, similar to that of CYP1A1 and CYP1A2, but exhibits a different dose-response to TCDD compared with the CYP1A isozymes.
Sequence analysis shows that CYP1B1 shares significant sequence identity with CYP1A1 and CYP1A2 in both rodents and humans (5) (6) (7) (8) . To generate antibodies that would identify both rat and human CYP1 isozymes, and to obviate any problems of antibody sub-family specificity, we designed cDNA expression constructs that exhibited low protein sequence similarity between the CYP1A and CYP1B1 subfamilies, while maintaining high sequence similarity between the rat and human orthologues of either CYP1A1 or CYP1B1, respectively. These constructs were expressed as hexahistidinetagged fusion proteins and purified from E.coli. We determined the sensitivity and specificity of these antibodies and used them to investigate the induction of CYP1B1 protein in Sprague-Dawley rats. As predicted on the basis of similarity of the primary amino acid sequence, these antibodies were cytochrome P450 subfamily specific and recognized the orthologous proteins from either human or rodents. Also as predicted, the antibodies raised against the CYP1A1 polypeptide were shown to cross-react with CYP1A2. The anti-CYP1B1 and anti-CYP1A1 antibodies detected as little as 0.01 pmol of CYP1B1 and 0.2 pmol of CYP1A1 protein, respectively, indicating a level of sensitivity sufficient for the analysis of expression of these proteins in the liver and other organs in untreated animals.
We used these antibodies to demonstrate the induction of CYP1B1 protein in the livers of female Sprague-Dawley rats following both acute high-dose and chronic exposure to TCDD. These analyses extend our previous observations of the increase of CYP1B1 RNA levels in rat liver by a relatively high dose of TCDD (25 µg/kg body wt) and showed that TCDD exposure at this dose results in an increase in CYP1B1 protein in vivo. In addition, we showed that CYP1B1 is also induced following chronic treatment with up to 125 ng TCDD/kg/day for 30 weeks. Chronic treatment of Sprague-Dawley rats with 100 ng TCDD/kg/day for 2 years resulted in a significant increase in liver tumors in female, but not male rats (22) . In a 30-week tumor promotion study (18) exposure of DEN-initiated female Sprague-Dawley rats to an approximate daily dose of 125 ng/ kg/day led to a significant increase in altered hepatic foci and cell proliferation (18) . The observation that CYP1B1 was induced at a carcinogenic dose indicates the induction of CYP1B1 protein is not a high dose phenomenon and that the further analysis of CYP1B1 in a context of a chronic tumor promotion model may aid in our understanding of the mechanism of carcinogenesis of TCDD.
Analysis of dose-response indicated that in contrast to CYP1A1 and CYP1A2, maximal induction of CYP1B1 protein may occur at a greater tissue dose of TCDD. At a dose of 1000 ng/kg, CYP1B1 was barely detectable, whereas CYP1A1/ 1A2 were almost maximally induced. This observation supports a recent report showing that CYP1B1, CYP1A1 and CYP1A2 exhibit different dose-responses to TCDD (23) . An acute dose of 1000 ng/kg results in a liver TCDD burden of~7 ppb which is the same as that seen in the livers of animals exposed chronically to TCDD at an average daily dose of 35 ng/kg/ day for 30 weeks (16, 18) .
One possible explanation for this observed difference may 
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be that CYP1B1 is induced in different areas within the liver. This was examined by immunohistochemical analysis of livers obtained from animals exposed to 35 ng TCDD/kg/day for 30 weeks. The data showed that CYP1B1 was undetectable in control livers whereas the CYP1A isozymes were observed in hepatocytes around the central vein. Previous studies have demonstrated specific expression of CYP1A2 in hepatocytes around the central veins of untreated rat liver (17) , and therefore the observed staining with the CYP1A1 antibody likely represents staining of CYP1A2. In TCDD-treated animals both CYP1B1 and the CYP1A isozymes were expressed in hepatocytes in the centrilobular region of the liver in TCDD-treated animals, but not in periportal regions. The specificity of the antibodies in rat liver microsomal fractions and the lack of reactivity using normal rabbit serum as a negative control, indicated that acinar zone pattern of expression observed in the TCDD-treated rat liver was most likely due to specific P450 staining. This acinar zone pattern of induction of CYP1A1 and CYP1A2, is consistent with several previous reports showing that the induction by TCDD of both CYP1A1 and CYP1A2 occurs in the centrilobular region of the liver (17, 21, 24) . Furthermore, it shows that the differences in dose-response between the CYP1A and CYP1B1 isozymes is not due to differences in the type of cell responding in the liver, but is likely due to differences in the magnitude of the individual cellular response and/or the number of cells responding in the liver. It will be important to determine the different shapes of the dose-response curves for CYP1B1 and the CYP1A isozymes, and whether the observed differences are due to differences in gene expression and/or differential induction of the CYP1 isozymes in subsets of hepatocytes across the liver acinus at low doses of TCDD. The mechanism for the acinar-specific induction of the CYP1 isozymes by TCDD is unknown, but probably reflects differences in the cellular biology of hepatocytes across the liver acinus. It is likely that the centrilobular pattern of expression is not related to differences in distribution of TCDD in the liver. During a chronic dosing regimen, tissue levels of TCDD are believed to be at equilibrium and it is assumed that the concentration of TCDD is constant throughout the liver. In support of this belief, other effects of TCDD, such as the down regulation of the epidermal growth factor receptor and increases in cell proliferation, do not exhibit a zonal-specific pattern (25) . Consequently, there may be specific factors that modulate the induction of the CYP1 isozymes in response to TCDD in different regions of the liver. The expression of CYP1A2 in liver of untreated animals and the observation of distinct induction of CYP1A1/CYP1A2 and CYP1B1 indicate that there are likely to be both common and unique mechanisms of regulation of the CYP1 isozymes. The ability to detect and quantify CYP1B1 protein in rodents and humans will facilitate an improved understanding of the function and regulation of this enzyme, as well as its possible role in toxic responses.
